Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cardiac Magnetic Resonance Imaging, Acute Myocardial Infarction (AMI), PET / MR. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \[PCI\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET/MR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET/MR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.
Primary outcome measures
- The myocardial uptake of 18F-Pentixafor was quantified using SUVmax and SUVmean values derived from PET imaging. [Time frame: At baseline (within 1 week of enrollment)]
- Left ventricular ejection fraction (LVEF) assessed by cardiac MRI to evaluate left ventricular function [Time frame: At baseline (within 1 week of enrollment)]
- Infarct Characterization [Time frame: At baseline (within 1 week of enrollment)]
Secondary outcome measures (3)
- Myocardial T1 Values and Extracellular Volume (ECV) [Time frame: At baseline (within 1 week of enrollment)]
- Myocardial T2 values [Time frame: At baseline (within 1 week of enrollment)]
- Myocardial Strain Analysis [Time frame: At baseline (within 1 week of enrollment)]
Eligibility criteria
Inclusion criteria
- Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure.
Exclusion criteria
- Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions.
Patients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural/functional assessments.
Prior history of myocardial infarction, coronary revascularization (PCI/CABG).
Concurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic/autoimmune diseases, or severe hepatic/renal failure.
Contraindications to CMR (claustrophobia, pacemaker implantation, etc.).
Pregnant, breastfeeding, or women of childbearing potential without effective contraception.
Sexually active individuals of reproductive age unwilling to use reliable contraception.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The Affiliated Hospital of Qingdao University — Qingdao
Identifiers
NCT: NCT07130409 · QYFYECR2025-74